Vol 3, No 1 (2011)
Mol Cell Pharmacol
Table of Contents
PharmSights
| Focus on α4β2* and α6β2* nAChRs for Parkinson’s Disease Therapeutics | Abstract PDF |
| Xiomara A Pérez, Maryka Quik | 1-6 |
| Molecular Pharmacological Approach Reveals Potential New Strategies to Suppress Androgen Receptor Signaling in Prostate Cancer | Abstract PDF |
| Tetsuo Mashima, Sachiko Okabe, Hiroyuki Seimiya | 7-12 |
| STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents | Abstract PDF |
| Sarah R Walker, Mousumi Chaudhury, David A Frank | 13-19 |
Research Articles
| Evaluation of Anticancer Properties of Medicinal Plants from the Indian Sub-Continent | Abstract PDF |
| Akbar Nawab, Mohammad Yunus, Abbas A Mahdi, Sanjay Gupta | 21-29 |
Reviews
| Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis | Abstract PDF |
| Shi-Yong Sun | 31-34 |
FDA Corner
| FDA Approves Edarbi to Treat High Blood Pressure | Abstract PDF |
| 35 |
| FDA Approves Drug to Reduce Risk of Preterm Birth in At-risk Pregnant Women | Abstract PDF |
| 35-36 |
| FDA Approves Viibryd to Treat Major Depressive Disorder | Abstract PDF |
| 36 |
| FDA Approves Head Lice Treatment for Children and Adults | Abstract PDF |
| 36-37 |
Our partner: Crossroads Pharmacy 2800 Hwy 101, Rogersville, AL 35652 LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041 Copyright © 2008 LumiText Publishing. All rights reserved.